Within Major Pharmaceutical Preparations industry Intellipharmaceutics International Inc booked the highest Quick Ratio than Intellipharmaceutics International Inc in the third quarter 2023. While total ranking remained the same in the Q3 2023 compared to the second quarter 2023 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents IPCIF�s has?
What are IPCIF�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

IPCIF Quick Ratio	(Aug 31 2023) Q3	(May 31 2023) Q2	(Feb 28 2023) Q1	(Nov 30 2022) Q4	0 Q3
Y / Y Current Liabilities Change	29.79 %	24.82 %	8.24 %	0.55 %	-10.69 %
Y / Y Cash & cash equivalent Change	-	-	-67.1 %	-89.15 %	-92.81 %
Quick Ratio MRQ	-	-	0.01	0.02	0.01
IPCIF's Total Ranking	#	#	#	#	#
Seq. Current Liabilities Change	7.69 %	26.3 %	3.43 %	-7.74 %	3.56 %
Seq. Cash & cash equivalent Change	-	-	-16.93 %	5.11 %	-78.63 %

Quick Ratio third quarter 2023 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Overall Market	#

Quick Ratio Statistics
High	Average	Low
0	0	0

Financial Statements
Intellipharmaceutics International Inc 's Current Liabilities	$ 8 Millions	Visit IPCIF's Balance sheet
Intellipharmaceutics International Inc 's Cash & cash equivalent	$ 0 Millions	Visit IPCIF's Balance sheet
Source of IPCIF's Sales		Visit IPCIF's Sales by Geography

Cumulative Intellipharmaceutics International Inc 's Quick Ratio

IPCIF's Quick Ratio for the trailling 12 Months

IPCIF Quick Ratio	(Aug 31 2023) 12 Months	(May 31 2023) 12 Months	(Feb 28 2023) 12 Months	(Nov 30 2022) 12 Months	0 12 Months
Y / Y Current Liabilities TTM Growth	16.34 %	5.09 %	-6.3 %	-14.16 %	-13.94 %
Y / Y Cash & cash equivalent TTM Growth	-89.32 %	-90.55 %	-86.72 %	-83.58 %	-63.95 %
Quick Ratio TTM	0.01	0.01	0.03	0.03	0.06
Total Ranking TTM	#	#	#	#	#
Seq. Current Liabilities TTM Growth	7.3 %	6.24 %	1.93 %	0.13 %	-3.08 %
Seq. Cash & cash equivalent TTM Growth	-34.2 %	-61.55 %	-18.97 %	-47.93 %	-41.73 %

Quick ratio ranking by company, industry and sector >> Back to IPCIF Financial Strength Comparisons >> Go to Compare IPCIF Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the unchanged in Current Liabilities in the Q3 2023 to $7.65 millions, cumulative Quick Ratio remained unchanged at 0.01 above the IPCIF average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry IPCIF achieved the highest Quick Ratio. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2023 at 4735.

Explain Quick Ratio?
How much Cash & cash equivalents IPCIF�s has?
What are IPCIF�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
0	0	0

Companies with similar Quick Ratio in the quarter ending Aug 31 2023, within Major Pharmaceutical Preparations Industry

Quick Ratio

Aug 31 2023 MRQ Cash & cash equivalent

Aug 31 2023 MRQ Current Liabilities

Date modified: 2026-09-12T06:20:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.